Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) reported Q3 2017 earnings this Morning, coming in at ($1.59) per share, beating Wall Street’s estimates of ($1.78) per Share. Revenue for the quarter came in at $11.35 million beating analyst estimates of $10.85 million
Analyst Coverage For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
These are 1 Hold Rating, 11 Buy Ratings .
The current consensus rating for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is Buy (Score: 2.92) with a consensus target price of $75.20 , a potential (17.01% upside)Recent Insider Trading for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
- On 10/17/2017 Lewis Clayton Jr. Cantley, Director, sold 4,000 with an average share price of $71.10 per share and the total transaction amounting to $284,400.00.
- On 10/16/2017 Lewis Clayton Jr. Cantley, Director, sold 1,000 with an average share price of $71.09 per share and the total transaction amounting to $71,090.00.
- On 10/4/2017 David P Schenkein, CEO, sold 80,000 with an average share price of $70.14 per share and the total transaction amounting to $5,611,200.00.
- On 10/4/2017 Scott Biller, Insider, sold 10,470 with an average share price of $70.00 per share and the total transaction amounting to $732,900.00.
- On 10/2/2017 David P Schenkein, CEO, sold 6,000 with an average share price of $66.76 per share and the total transaction amounting to $400,560.00.
- On 10/2/2017 Scott Biller, Insider, sold 2,146 with an average share price of $67.23 per share and the total transaction amounting to $144,275.58.
Recent Trading for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares of Agios Pharmaceuticals, Inc. closed the previous trading session at with shares trading hands.